Bis-indole-derived NR4A1 antagonists inhibit colon tumor and splenic growth and T-cell exhaustion
Cancer Immunology, Immunotherapy · 2023-12 · 72 (12) · 3985-3999
DOI: 10.1007/s00262-023-03530-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 17.10.2023. Verfasst von Kumaravel Mohankumar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX, 77843, USA. Hauptthemen laut MEDLINE: B7-H1 Antigen, Colonic Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS, NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
There is evidence that the orphan nuclear receptor 4A1 (NR4A1, Nur77) is overexpressed in exhausted CD8 + T cells and regulates PD-L1 in tumors. This study investigated the effects of potent bis-indole-derived NR4A1 antagonists on reversing T-cell exhaustion and downregulating PD-L1 in colon tumors/cells. NR4A1 antagonists inhibited colon tumor growth and downregulated expression of PD-L1 in mouse colon MC-38-derived tumors and cells. TILs from MC-38 cell-derived colon tumors and splenic lymphocytes exhibited high levels of the T-cell exhaustion markers including PD-1, 2B4, TIM3+ and TIGIT and similar results were observed in the spleen, and these were inhibited by NR4A1 antagonists. In addition, treatment with NR4A1 antagonists induced cytokine activation markers interferon γ , granzyme B and perforin mRNAs and decreased TOX, TOX2 and NFAT in TIL-derived CD8 + T cells. Thus, NR4A1 antagonists decrease NR4A1-dependent pro-oncogenic activity and PD-L1 expression in colon tumors and inhibit NR4A1-dependent T-cell exhaustion in TILs and spleen and represent a novel class of mechanism-based drugs that enhance immune surveillance in tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX, 77843, USA.
- Department of Veterinary Pathobiology, Texas A&M University, College Station, TX, 77843, USA.
- TAMU Flow Cytometry Facility, Texas A&M University, College Station, TX, 77843, USA.
- Department of Medical Physiology, College of Medicine, Texas A&M University, College Station, TX, 77843, USA.
- Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, 77843, USA.
- Houston Methodist Cancer Center, Institute of Academic Medicine and Weill Cornell Medical College, Houston, TX, 77030, USA.
Förderung
- NIEHS NIH HHS
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
- Houston Methodist Research Institute
- Texas AgriLife Research
- Allen Endowed Chair in Nutrition and Chronic Disease Prevention
Zitieren
APA
Mohankumar, K., Wright, G., Kumaravel, S., Shrestha, R., Zhang, L., Abdelrahim, M., Chapkin, R. S., & Safe, S. (2023). Bis-indole-derived NR4A1 antagonists inhibit colon tumor and splenic growth and T-cell exhaustion. Cancer Immunology, Immunotherapy, 72(12), 3985-3999. https://doi.org/10.1007/s00262-023-03530-3
Vancouver
Mohankumar K, Wright G, Kumaravel S, Shrestha R, Zhang L, Abdelrahim M, et al. Bis-indole-derived NR4A1 antagonists inhibit colon tumor and splenic growth and T-cell exhaustion. Cancer Immunology, Immunotherapy. 2023;72(12):3985-3999. doi:10.1007/s00262-023-03530-3
BibTeX
@article{Mohankumar2023,
author = {Mohankumar, Kumaravel and Wright, Gus and Kumaravel, Subhashree and Shrestha, Rupesh and Zhang, Lei and Abdelrahim, Maen and Chapkin, Robert S and Safe, Stephen},
title = {Bis-indole-derived NR4A1 antagonists inhibit colon tumor and splenic growth and T-cell exhaustion},
journal = {Cancer Immunology, Immunotherapy},
year = {2023},
volume = {72},
number = {12},
pages = {3985--3999},
doi = {10.1007/s00262-023-03530-3}
}
EUVIMED